Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumors 1Pancreatic Neoplasms 1Haematological Malignancies 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × MSC1992371A × Clear all
NCT00391521 2014-01-30

AS703569 Phase I in Patients With Solid Tumours

EMD Serono

Phase 1 Completed
104 enrolled
Other solid neoplasm

Solid Tumors

NCT01097512 2014-01-30

AS703569 and Gemcitabine Combination in Advanced Malignancies

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
66 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01080664 2013-10-22

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

EMD Serono

Phase 1 Terminated
124 enrolled

Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡